Kenya and Uganda are rolling out the long-acting injectable HIV prevention medication, Lenacapavir, a significant advancement in combating the epidemic.

• The injectable is administered once every six months, a key benefit over daily oral pills.
• Key partners include the Global Fund to Fight AIDS, Tuberculosis and Malaria and the U.S. government.
• The rollout targets populations at elevated risk, including adolescent girls and young women, with distribution of initial doses set to begin in March 2026 in Uganda.